Randomized trial · people
Tirzepatide: better sleep and quality of life scores in SURMOUNT-OSA
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Beyond fewer breathing pauses during sleep, people with sleep apnea on tirzepatide in this trial said they slept, functioned and felt better than those on placebo.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2025
- Journal
- Sleep Med
What they tested
The team tested whether tirzepatide changed how people with obstructive sleep apnea and obesity rated their own sleep, daytime functioning, symptoms and quality of life.
How the study was done
Two randomized, placebo-controlled phase 3 trials gave people with moderate-to-severe obstructive sleep apnea and obesity tirzepatide (10 mg or 15 mg) or placebo, an inactive dummy treatment, for 52 weeks. In Study 2, people who used PAP, a breathing therapy for sleep apnea, stopped it before their sleep tests and questionnaires.

Model. Individual results vary.
What they found
At 52 weeks, people on tirzepatide reported significantly better scores than placebo on questionnaires about sleep-related impairment, sleep disturbance, activity level and health-related quality of life, plus most areas of a general health survey. They also rated their overall symptom status and change as better than the placebo group did. Daytime sleepiness scores changed significantly in Study 1.
What it doesn’t show
These are self-reported questionnaire results over 52 weeks in people with moderate-to-severe sleep apnea and obesity, so they may not apply to milder sleep apnea or to people without obesity. The sleepiness result was significant in Study 1 only.
The paper
Kanu et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. Sleep Med. 2025.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeksRandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.